<DOC>
	<DOC>NCT00942604</DOC>
	<brief_summary>The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.</brief_summary>
	<brief_title>A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Must be male or female and at least 18 years of age. Female patients must be of: Nonchildbearing potential; Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception. 4 to 8 AK lesions on nonhead locations. Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area. Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks. Treatment with 5FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>